EN NL FR

Immunointerventions in new-onset patients or high-risk relatives: slowing down or preventing type 1 diabetes

Studies with immunotherapy

Type 1 diabetes is caused by a strong reduction in the number of insulin-producing cells in the pancreas (beta-cells). These cells are being destroyed by a specific type of white blood cells.

As type 1 diabetes is considered animmune-mediated disease, the Belgian Diabetic Register is currently involved in immunointervention studies aiming to slow down the natural disease course.

Currently there are no studies ongoing in high-risk relatives. Presently, there is one ongoing study with immunotherapy (DIABIL-2 study) actively recruiting new-onset patients. The recruitment is organized by the BDR. The current study is for patients between 6-35 years old who had the diagnosis of type 1 diabetes since less than two months.
For more information: contact your specialist.

Diabil study

Future:

There are more immunological studies to come. Contact your BDR – diabetologist or pedatrician for further information.